New Massachusetts legislation bans the sale of menthol products; a group of hospitals is suing HHS; the FDA has approved a new treatment for partial-onset seizures.
A bill passed by Massachusetts lawmakers would ban sales of flavored tobacco and vaping products, including menthol cigarettes, according to the Associated Press, as well as impose a 75% excise tax on vaping products and require insurers to cover counseling for tobacco cessation. It was in September that Governor Charlie Baker first introduced a temporary 4-month ban, although he has not yet indicated whether he will sign the new bill. If it goes into law on June 1, 2020, it would be the first law of its kind in the nation.
Thirteen hospitals and Capital Health System have filed a lawsuit in the US District Court for the District of Columbia against HHS and HHS Secretary Alex Azar, according to Bloomberg Law. The hospitals claim they were not correctly reimbursed for services provided to low-income patients after a 2014 change in the calculation of such payments. They seek a declaration that the HHS decision is invalid and an order of new recalculation and repayment, along with attorneys’ fees and costs.
Based on findings from 2 studies, yesterday the FDA approved cenobamate (Xcopri), a new antiepileptic drug from SK Life Science that treats partial-onset seizures in adults. The drug has a maximum recommended dose of 400 mg when necessary, but in most cases, the dose will be 200 mg daily. Possible adverse effects include changes in mood or behavior, sleepiness, and headaches.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Team Coordination, Data Sharing Help Prioritize Value in Cardio-Renal-Metabolic Care
September 12th 2025Cardiologists, nephrologists, and payers met in Scottsdale, Arizona, on August 26, 2025, to share insights on how team members can work together, empowered by data, to achieve value-based management of cardio-renal-metabolic syndrome.
Read More